Stock Ratings / Health Care / RGNT / options

CLGN (50) CUPR (32) LFWD (46) HSCS (43) ⌘ Pro Terminal →

Regentis Biomaterials Ltd. (RGNT) Options Positioning, Max Pain & Unusual Sweeps

$1.36 +10.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.38

Regentis Biomaterials Ltd. (RGNT) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $9.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.38 (+1.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY RGNT SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.60-6.9% Next Q

Q2 (-2Q)

Grade D$1.49-14.1% Next Q

Q3 (-1Q)

Grade D$1.28+6.3% Next Q

Current

Grade D$1.36-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RGNT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RGNT currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.78) and Max Pain ($1.43) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RGNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RGNT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RGNT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNT)

✓Walkthrough of RGNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RGNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.26%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.42H $1.42L $1.31C $1.36VOL 24.9K

RES: $2.67SUP: $1.21SMA50: $1.78SMA200: $2.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGNT Butterfly Map → + Track RGNT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RGNT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGNT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RGNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNT)

Health Care Rank #527 of 1016 ⚔️ CLGN vs RGNT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGNT vs. CLGN, CUPR, LFWD, HSCS)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Regentis Biomaterials Ltd. (RGNT) ranks #527 by composite RQD confidence (44/100, grade D) and #899 by equity capitalization ($9.6M). Within this direct 5-issuer industry benchmark cohort, RGNT leads on earnings valuation at N/A trailing P/E, while RGNT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with RGNT at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RGNT ACTIVE Regentis Biomaterials Ltd.	D	44/100	—	—	-35.0%	+10.57%	$9.6M	Benchmark Subject
CLGN CollPlant Biotechnologies Ltd	D	50/100	—	64.8%	-35.0%	+11.39%	$12.7M	/clgn-vs-rgnt →
CUPR Cuprina Holdings (Cayman) Limited (Class A)	E	32/100	—	-1.3%	-35.0%	-1.07%	$14.1M	/cupr-vs-rgnt →
LFWD Lifeward Ltd.	D	46/100	—	96.0%	-35.0%	+2.78%	$16.7M	/lfwd-vs-rgnt →
HSCS HeartSciences Inc.	D-	43/100	—	59.1%	-35.0%	+7.12%	$17.5M	/hscs-vs-rgnt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001912966

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$1.4M, and free cash flow of -$1.4M (-114.5% YoY). On the balance sheet, RGNT closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.6M	-$1.4M	-$1.4M	$7.6M	—
FY2024 (FY)	2024-12-31	$0	$4.8M	-$641.0K	-$641.0K	$482.0K	—
FY2023 (FY)	2023-12-31	$0	-$4.1M	-$1.2M	-$1.2M	—	—

3. RGNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.36 (+10.57% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RGNT ranks #527 in composite RQD confidence.

How does RGNT compare to CLGN and CUPR in the Health Care sector?

Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RGNT?

Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $0 in revenue, -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RGNT trading relative to its 50-day, 200-day, and 52-week technical levels?

RGNT last traded at $1.36 (+10.57% on volume of 61,904 shares), positioning the stock -23.60% below its 50-day simple moving average ($1.78) and -53.42% below its 200-day simple moving average ($2.92). Across its 52-week range of $1.23 to $15.50, RGNT sits at the 0.9% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).